Urdoksa caps. 250mg 50 pieces

$15.60

Urdoksa caps. 250mg 50 pieces

Quantity:

Description

Composition
Active substance:
1 capsule contains: 250 mg of ursodeoxycholic acid.
Excipients:
Corn Starch – 73.0 mg Colloidal anhydrous silica – 5.0 mg magnesium stearate – 2.0 mg.
Hard gelatin capsule: gelatin – 98% titanium dioxide (E171) – 2%.
Description:
White or almost white, opaque hard gelatin capsules N0. Contents of capsules: white or almost white granules.
Product form:
Capsules 250 mg.
10 capsules in blisters of PVC film and aluminum foil printed patent.
50 or 100 capsules in polymeric cans or jars with lids for polymer drugs. banks cover may be made of yellow plastic.
On each bank adhesive label paper writing or self-adhesive label or a label.
According to one bank or 1,2,3,4,5,6,7,8,9 or 10 contour of cellular packaging together with instructions for use placed in a cardboard box.
Contraindications
Rentgenopolozhitelnye (high calcium) gallstones; nonfunctioning gallbladder; acute inflammatory diseases of the gall bladder, bile ducts and intestine; cirrhosis of the liver decompensation; expressed human kidney, liver, pancreas; hypersensitivity to the drug.
Ursodeoxycholic acid has no age restrictions in the application, but for children under 3 years did not use the drug in the dosage form.
Used with caution in children under the age of 3 to 4 years, as possible difficulty swallowing capsules.
Dosage
250 mg
Indications
Primary biliary cirrhosis, with no signs of decompensation (symptomatic treatment); the dissolution of cholesterol gallstones; biliary reflux gastritis; primary sclerosing cholangitis; Alcoholic liver disease; nonalcoholic steatohepatitis; cystic fibrosis (cystic fibrosis); chronic hepatitis of various genesis; biliary dyskinesia.
Interaction with other drugs
Cholestyramine, colestipol, antacids that contain aluminum hydroxide or smectite (aluminum oxide), reduce the absorption of UDCA in the intestine and thereby reduce its absorption and efficacy. If the application of formulations containing at least one of these substances is necessary, they should be taken at least 2 hours before receiving Urdoksa® preparation.
Ursodeoxycholic acid can enhance cyclosporine absorption from the intestine. Therefore, patients taking cyclosporine, you should check the concentration of cyclosporine in the blood and adjust the dose of cyclosporine if necessary.
In some cases Urdoksa® drug may reduce the absorption of ciprofloxacin.
Lipid-lowering drugs (particularly clofibrate), estrogens, progestins, or neomycin increase saturation bile cholesterol and may reduce the ability to dissolve cholesterol gallstones.
You should inform your doctor about all medications you are taking.
Overdose
Overdose Cases of UDCA unknown. carrying out symptomatic treatment is recommended in cases of overdose.
pharmachologic effect
Pharmacological group:
Hepatoprotective agent.
Pharmacodynamics:
Hepatoprotective drug also has choleretic, cholelitolitic, hypocholesterolemic, hypolipidemic, immunomodulating action.
Fitting into the hepatocyte membrane stabilizes its structure and to protect the hepatocyte from the damaging effect of bile salts, thereby reducing their cytotoxic effect. In cholestasis activates Ca2 + -dependent protease and alpha-stimulated exocytosis, reduces the concentration of toxic bile acids (chenodeoxycholic, lithocholic, deoxycholic et al.) Whose concentrations in patients with chronic liver disease increased.
Competitive reduces the absorption of lipophilic bile acids in the intestine, increases their “Fractional” turnover under enterohepatic circulation cholepoiesis induces, promotes the passage of bile and excretion of toxic bile acids across the gut.
Screens nonpolar bile acid (chenodeoxycholic) thereby forming mixed (nontoxic) micelle.
Reduces the saturation of bile with cholesterol by decreasing cholesterol synthesis and secretion in the liver and inhibiting its absorption in the intestine.
Increases the solubility of cholesterol in the biliary system, it stimulates the production and secretion of bile. Decreases lithogenicity bile, it increases the concentration of bile acids causes increased gastric and pancreatic secretion, increases lipase activity, exerts hypoglycemic action.
Causing partial or complete dissolution of cholesterol gallstones, reduces the saturation of bile with cholesterol, which contributes to its mobilization of gallstones.
Has immunomodulatory effects, influences the immunological reaction in the liver: decrease the expression of certain histocompatibility antigens – HLA-1 on the membrane of hepatocytes and HLA-2 cholangiocytes, affects the amount of T-lymphocytes, interleukin 2, reduces the number of eosinophils, inhibit immunocompetent Ig (in primarily IgM).
Pharmacokinetics:
Ursodeoxycholic acid is absorbed in the small intestine due to passive diffusion (approximately 90%) and in the ileum by an active transport. The maximum plasma concentration (Cmax) when administered at a dose of 50 mg every 30, 60, 90 min – 3.8 mmol / l 5.5 mmol / l and 3.7 mmol / l, respectively. Cmax is achieved in 1-3 hours.
Relationship to plasma proteins is high – up to 96-99%. It crosses the placental barrier. In the systemic drug reception becomes ursodeoxycholic acid in the serum and the primary bile acid is about 48% of the total bile acids in the blood. The therapeutic effect of the drug depends on the concentration of UDCA in bile.
It is metabolized in the liver (the clearance in the “first pass” through the liver) in the taurine and glycine conjugates. The resulting conjugates are secreted into bile.
Approximately 50-70% of the dose is excreted in the bile. A small number nevsosavsheysya ursodeoxycholic acid enters the colon, where bacteria undergoes cleavage (7-dehydroxylation); lithocholic acid formed partially absorbed from the colon but sulfated in the liver and excreted as rapidly sulfolitoholilglitsinovogo or sulfolitoholiltaurinovogo conjugate.
Pregnancy and breast-feeding
In experimental animal studies revealed no mutagenic and carcinogenic effects of UDCA. UDCA during pregnancy is possible only when the expected benefit to the mother outweighs the potential risk to the fetus (adequate well-controlled studies of ursodeoxycholic acid was conducted in pregnant women).
If necessary, use during lactation should decide the issue of termination of breastfeeding. Data on the allocation of ursodeoxycholic acid in breast milk are not currently available.
Conditions of supply of pharmacies
On prescription.
side effects
The frequency of adverse reactions is given in accordance with the following scale: very often (> 10%); frequent (> 1% and
special instructions
Urdoksa® the drug must be used under medical supervision.
In applying the drug to dissolve gallstones is necessary that the following conditions are met: the stones should be cholesteric (roentgen), their size must not exceed 15-20 mm, the gallbladder must remain functional and be filled with stones not more than half, and the patency of the cystic common bile duct should be maintained. With prolonged (over 1 month) taking the drug every 4 weeks during the first 3 months of treatment, further – every 3 months is necessary to carry out a biochemical blood test for determining the activity of hepatic transaminases. Monitoring the effectiveness of the treatment should be carried out every 6 months by ultrasound of biliary tract. After complete dissolution of the stones is encouraged to continue to use the drug for at least 3 months, in order to facilitate the dissolution of the stones residues dimensions which are too small to be detected and for preventing recurrence of stone formation.
In patients with primary biliary cirrhosis, in rare cases, clinical symptoms may worsen at the start of treatment, eg the itching may increase. In this case, treatment should be continued, taking 1 capsule daily, the dosage should be increased further (increasing the daily dose every week by 1 capsule) as long as the new will not reach the recommended dosing regimen.
In the case of adverse or serious reactions to the patient should immediately inform your doctor about them and, in any case, do not continue to use the drug without his recommendation.
Effects on ability to drive vehicles and operate machinery have been identified.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Urdoksa® capsule taken by mouth without chewing, drinking a small amount of water.
Symptomatic treatment of primary biliary cirrhosis
The daily dose depends on the body weight and from 3 to 7 capsules (approximately 14 ± 2 mg of ursodeoxycholic acid per 1 kg of body weight). In the first 3 months of treatment with the drug Urdoksa® should be divided into several doses throughout the day. After the improvement of hepatic parameters daily dose can be administered 1 time in the evening.
We recommend the following application conditions:
Body weight The daily dose in the morning afternoon evening 34-46 kg capsule 1 2 – 1 kg 47-62 capsule 3 1 1 1 4 63-78 kg capsule 1 1 2 79-93 kg 5 2 2 1 capsule 94-109 kg 6 capsules 2 February 2
More than 110 kg capsules 7 2 2 3
Urdoksa® drug should be taken regularly. Duration of therapy – for an unlimited time.
Dissolution of cholesterol gallstones
The recommended dose is 10 mg of ursodeoxycholic acid per 1 kg of body weight per day, which corresponds to:
Body Weight Daily dose
60 kg 61-80 kg capsule 2 capsule 3 capsule 4 81-100 kg
Over 100 kg 5 capsules
Urdoksa® medication must be taken daily in the evening, before bedtime. The duration of therapy is 6-12 months. For prevention of recurrence of cholelithiasis is recommended taking the drug for several months after the dissolution of stones.
Treatment of biliary reflux gastritis 1 capsule Urdoksa® drug daily 1 time a day at bedtime. The course of treatment 10-14 days to 6 months, if necessary, up to 2 years.
Primary sclerosing cholangitis
The daily dose is 12-15 mg / kg; if necessary, the dose may be increased to 20-30 mg / kg 2-3 hours. Duration of therapy is from 6 months to several years.
Alcoholic liver disease
The average daily dose is 10-15 mg / kg 2-3 hours. The duration of therapy is 6-12 months or more.
nonalcoholic steatohepatitis
The average daily dose is 10-15 mg / kg 2-3 hours. The duration of therapy is 6-12 months or more.
Cystic fibrosis (mucoviscidosis)
The daily dose is 12-15 mg / kg; if necessary, the dose may be increased to 20-30 mg / kg 2-3 hours. The duration of therapy is 6 months to a few years or for life.
Chronic hepatitis of various genesis
The daily dose is 10-15 mg / kg 2-3 hours. Duration of treatment is 6 to 12 months or more.
Biliary dyskinesia
The average daily dose is 10 mg / kg in 2 hours. Duration of therapy is from 2 weeks to 2 months. If necessary, treatment is recommended to repeat.
Children older than 3 years of drug administered individually at the rate of 10-20 mg / kg / day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Obolensky

There are no reviews yet.

Add your review